April 2017 Default Cover Image
Do you prescribe MET for stone patients?Urology Times reached out to three urologists (selected randomly) and asked them each the following question: Do you prescribe MET for stone patients?
What’s new in prostate Ca tests: Markers, imagingIn this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Biomarkers for bladder cancer: Current and futureThe role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
18F-choline PET/CT detects PCa recurrences earlyThree out of four patients with prostate cancer with an 18F-choline positron emission tomography/computed tomography–detected recurrence were potentially salvageable with local therapy or metastasis-directed therapy, according to results of the screening phase of the phase II STOMP randomized trial.
Medicaid not reducing racial disparity in PCa outcomesAfrican-American men were more likely to present with metastases, less likely to receive definitive therapy, and had increased prostate cancer-specific mortality compared with non-African-American men regardless of whether they were privately insured or insured through Medicaid, a study presented at the Genitourinary Cancers Symposium in Orlando, FL found.
Updated prostate Bx paper outlines preventive strategiesA recently updated white paper from the AUA and the Society of Urologic Nurses and Associates includes new data on the prevalence of prostate biopsy-related complications and outlines the current preventive strategies. In this installment of "Journal Article of the Month," Badar M. Mian, MD, gives an overview and analysis of the updated paper.
New Products: Nasal spray to treat nocturia receives FDA approvalOther products discussed include catheter sets to make the ordering process easier, a micro-US/MRI fusion application for prostate imaging, an international prostate registry for HIFU and more.
Guarded approval for new USPSTF PSA gradeThe new draft recommendation on PSA screening from the U.S. Preventive Services Task Force (USPSTF), which improves the previous D rating for all men to a C rating for those ages 55 to 69 years, has been met with guarded approval by three of the key national organizations representing urologists.
Most men prefer informed decision-making for PCaParticipants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
MACRA: A practical perspective for urologistsThis article provides a practical explanation of MACRA and the Quality Payment Program and what they mean for practicing urologists.